anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intravenous infusion is a routing practice of drug administration for hospitalized children.However numerous studies have shown that venipuncture is a major source of pain of children during their hospitalization which can lead to moderate to severe pain and cause fear, stress and anxiety in children if there is no effective pain management.

The current pain relieving methods include pharmacological (i.e. topical anesthetic) and non-pharmnacological (i.e. distraction techniques) interventions. pharmacological There are scarce evidences supporting that a combination of pharmacological and non-pharmacological interventions can enhance children's abilities in coping with their pain and stress during the venipuncture. EMLA cream is a main pharmacological intervention in managing needle-related pain which can penetrate the cuticle and epidermal layer of intact skin, enter the dermis where nerve endings are located, and relieve pain. However pharmacological interventions have proven inadequate in mitigating pain and stress.The main non-pharmacological alternatives is distraction techniques. There are extremely limited data studies on merging pharmacological and non-pharmacological interventions to compensate for each other's inadequacies. Hence, this study aimed to evaluate the effect of combining both topical anesthetic and distraction techniques in comparison with either of the interventions applied singly.

This study adopts a randomized, blind, controlled intervention trial. Participants will be randomly assigned to three groups: EMLA group, Distraction group and Combined group (EMLA cream plus distraction techniques). The outcomes will be measured by self-reported pain, parent-reported pain and observer-reported pain. Salivary cortisol level will be measured by the ultra sensitive Cortisol Saliva ELISA Assay Kit. Other physiological metrics like heart rate, SpO2, and other intravenous cannulation factors will be rated and recorded.
Real-time Optimized Biofeedback Utilizing Sport Techniques (ROBUST) represents an innovative new approach to reduce traumatic anterior cruciate ligament (ACL) injuries. Over the last four decades, these debilitating injuries have occurred at a 2 to 10-fold greater rate in female compared to male athletes with the highest prevalence occurring between the ages of 16-18 years. As a consequence, there is a large population of females that endure significant pain, functional limitations and knee osteoarthritis (OA) as early as 5 years after the initial unintentional injury. To reduce the burden of OA, The National Public Health Agenda for Osteoarthritis recommends both expanding and refining evidence-based prevention of ACL injury. There currently is a gap in knowledge regarding how to maximize the effectiveness of injury prevention training in young female athletes. The long-term goal is to reduce ACL injuries in young female athletes. The objective of this application is to increase the efficacy of biofeedback training to reduce the risk of ACL injury. This proposal tests the central hypothesis that biofeedback methodology is needed to maximize the effectiveness of neuromuscular prophylactic interventions. The rationale supporting this proposal is that once the proposed research is completed, health professionals will be more successful at preventing devastating ACL injuries through properly optimized and targeted biofeedback training for young at-risk females. This research is innovative because it represents a new and substantive departure from the status quo by recognizing the need to optimize the application of biofeedback training. The work will contribute clinically relevant data in support of a future more robust clinical trial. The proposed research will be significant because it will lead to reduced rates of ACL injury in young females. Reduction of female injury rates to equal that of males would allow females annually to continue the health benefits of sports participation and avoid the long-term complications of osteoarthritis, which occurs with a 10 to 100-fold greater incidence in ACL-injured than in uninjured athletes.
The experimental group received a first nebulization of 5 mg of terbutaline(solution of 5mg/ 2 ml ) in association with 0.5 mg of ipratropium bromide (solution of 0.5 mg/ 2 ml) and 0.5 mg of budesonide (solution of 0.5 mg/2 ml) followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min. All patients received hydrocortisone hemisuccinate (100 mg i.v.) and O2 (7 l/ min) via a nebulizer.
BACKGROUND: Lumbar-iliac fixation (LIF) is a common treatment for Tile C1.3 pelvic fractures, but different techniques, including L4-L5/L5 unilateral LIF (L4-L5/L5 ULIF), bilateral LIF (BLIF), and L4-L5/L5 triangular osteosynthesis (L4-L5/L5 TOS), still lack biomechanical evaluation. The sacral slope (SS) is key to the vertical shear of the sacrum but has not been investigated for its biomechanical role in lumbar-iliac fixation. The aim of this study is to evaluate the biomechanical effects of different LIF and SS on Tile C1.3 pelvic fracture under two-legged standing load in human cadavers.
METHODS: Eight male fresh-frozen human lumbar-pelvic specimens were used in this study. Compressive force of 500 N was applied to the L4 vertebrae in the two-legged standing position of the pelvis. The Tile C1.3 pelvic fracture was prepared, and the posterior pelvic ring was fixed with L5 ULIF, L4-L5 ULIF, L5 TOS, L4-L5 TOS, and L4-L5 BLIF, respectively. Displacement and rotation of the anterior S1 foramen at 30° and 40° sacral slope (SS) were analyzed.
RESULTS: The displacement of L4-L5/L5 TOS in the left-right and vertical direction, total displacement, and rotation in lateral bending decreased significantly, which is more pronounced at 40° SS. The difference in stability between L4-L5 and L5 ULIF was not significant. BLIF significantly limited left-right displacement. The ULIF vertical displacement at 40° SS was significantly higher than that at 30° SS.
CONCLUSIONS: This study developed an in vitro two-legged standing pelvic model and demonstrated that TOS enhanced pelvic stability in the coronal plane and cephalad-caudal direction, and BLIF enhanced stability in the left-right direction. L4-L5 ULIF did not further improve the immediate stability, whereas TOS is required to increase the vertical stability at greater SS.
24 evaluable patients with radiological evidence of cerebral metastases on MRI will be enrolled into the study (12 who are treatment naïve + 12 who have completed Stereotactic Radiosurgery (SRS)+/- combination therapy). The patients invited to participate in the study will provide written informed consent. \[18F\]FPIA PET/MRI imaging will only be performed once patients have satisfied the inclusion and exclusion criteria. Once these have been satisfied, eligible patients will proceed to \[18F\]FPIA PET/MRI.

On the day of imaging the patients will undergo a blood test to measure plasma concentrations of carnitine (approximately 6mls). During the scan, a single dose of \[18F\]FPIA (maximum, 370 MBq) IV will be administered to the participant followed by a whole brain dynamic PET/MRI scan over 66 minutes. During the MRI sequences, the patient will receive a 2 stage IV bolus of Gadolinium contrast medium administered through a peripheral venous cannula.
The migrant caregivers who have randomly assigned into the control group will receive communication skills training (two 1.5-hour sessions) offered by another trained interventionist with psychology or social work background with at least three years of working experience working with older people. They would not receive any additional training on life story work.
OBJECTIVES: Centre-based childcare has been identified as a promising environment for obesity prevention in early childhood, but the longitudinal relationships between attending centre-based childcare and child obesity are not well understood. The objective of this systematic review is to evaluate the longitudinal associations between centre-based childcare attendance in early childhood and child body mass index compared with other childcare settings or parental care. Subgroup analyses will also be conducted to determine if socioeconomic factors and characteristics of the childcare setting modify the relationships.
METHODS: Databases that will be searched include MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Database and Web of Science. Longitudinal prospective cohort studies, retrospective cohort studies, case-control studies and intervention trials conducted in middle-income and high-income countries will be included in the search strategy. Sensitivity and subgroup analyses will be conducted to explore factors that may modify the findings. Study selection, data extraction, risk of bias and quality of evidence assessments will be conducted independently and in duplicate by two reviewers. Risk of bias will be assessed using the Risk Of Bias In Non-randomized Studies - of Exposure tool. Meta-analysis will be conducted using random effects models to account for between-study variation. Heterogeneity across included studies will be estimated using the I2 statistic. If meta-analysis is not possible, a narrative summary will be provided. The quality of the evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation tool.
ETHICS AND DISSEMINATION: Ethical approval is not required for this study since no data will be collected. Findings aim to inform interventions and guide efforts in childcare settings to support optimal child growth. Results will be published in a peer-reviewed journal. Results may be of relevance for childcare and public health policy, researchers, parents and healthcare practitioners.
PROSPERO REGISTRATION NUMBER: CRD42023436911.
The invention provides a composition containing bitter apricot seeds, a preparation method and application thereof. The composition can be used for preparing leisure food, health-care products or medicines with the effect of promoting bowel relaxing. The composition of the invention consists of raw materials of bitter almond and dried orange peel or extracts of the raw materials, and the mixture ratio is 7-35 parts of dried orange peel and 2-10 parts of bitter almond. The composition can be further prepared into pharmaceutically/food acceptable oral forms such as solid beverage, liquid beverage, mixture, soft extract, powder, tablet, capsule, granule, pill, oral liquid, etc. with diluent 0-77.42 weight parts, sour agent 0-0.1 weight parts, and/or essence 0-0.5 weight parts. The composition has better mouthfeel and controllable quality due to compatibility with the dried orange peel, has obvious effect of relaxing bowel, and has obvious improvement effect on the conditions of defecation frequency reduction, hard and dry feces, difficult defecation and the like.
Acamprosate calcium, USP is supplied in an enteric-coated tablet for oral administration. Acamprosate calcium, USP is a synthetic compound with a chemical structure similar to that of the endogenous amino acid homotaurine, which is a structural analogue of the amino acid neurotransmitter γ-aminobutyric acid and the amino acid neuromodulator taurine. Its chemical name is calcium acetylaminopropane sulfonate. Its chemical formula is C10H20N2O8S2Ca and molecular weight is 400.5. Its structural formula is:

Acamprosate calcium, USP is a white or almost white powder. It is freely soluble in water, practically insoluble in alcohol and in methylene chloride.

Each acamprosate calcium delayed-release tablet intended for oral administration contains 333 mg of acamprosate calcium, USP equivalent to 300 mg of acamprosate. In addition, each tablet contains the following inactive ingredients: colloidal anhydrous silica, methacrylic acid copolymer type c, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, sodium bicarbonate, sodium lauryl sulfate, sodium starch glycolate and talc. Sulfites were used in the synthesis of the drug substance and traces of residual sulfites may be present in the drug product.
Anxiety and stress are problems which are often seen in patients about to undergo upper GI endoscopy, and taking them under control is important in calming the person and in reducing complications. Studies have been conducted evaluating the effectiveness on these symptoms of various procedures such as aromatherapy, music therapy and reflexology in patients about to undergo upper GI endoscopy (Monfared, Mirzaee Jirdehi, Mansour Ghanaei, Joukar, \& Kazemnezhad Leyli, 2020; Shaermoghadam, Shahdadi, Khorsandvakilzadeh, Afshari, \& Badakhsh, 2016; Sogabe et al, 2018). Only one study was found which examined the effect of reiki on anxiety before colonoscopy (Hulse, Stuart-Shor, \& Russo, 2010), and no studies were found examining the effect of the implementation of reiki on levels of anxiety, stress and comfort in patients about to undergo upper GI endoscopy. This strengthens the particular value of this research. Also, it is thought that the results of this study will contribute to the literature in forming a basis for other studies on the topic. Therefore, the aim of the study was to evaluate the effect of the application of reiki and sham reiki on anxiety, stress and comfort levels in patients about to undergo upper GI endoscopy.This study had a randomized sham-controlled trial design. It was conducted between 2 February 2021 and 1 April 2021 in the Endoscopy Outpatients' Department of a state hospital in the Southeast Region of Turkey. In order to determine the applicability of the data collection form, a pre-application was conducted with 15 patients. The patients who were in the application group were not included in the sample group. The data were collected using the Patient Identification Form, the Visual Analog Scale for Stress (VASS), the State Anxiety Inventory (SAI) and the Short General Comfort Questionnaire (SGCQ).
The present invention provides systems and methods to realize the potential benefit of portable storage devices by taking advantage of standard PCs including an optical disk drive capable of reading an optical disk, such as a CD or a DVD, cost effective optical disks, and the Internet. In a preferred embodiment, an individual patient provides personal data to a healthcare service center. The healthcare service center then creates a portable optical disk for the patient to carry, if he/she so desires. The personal data that is written onto the portable optical disk is stored on a database management server database and is readable and updateable by the individual patient using his/her PC with an optical disk drive and connected to the Internet. The individual patient can choose to update his/her personal data on the portable optical disk and can receive a new portable optical disk that includes the update. The new portable optical disk containing the latest update is created and delivered to the patient by the database management server.
PURPOSE: To describe a surgical technique for oroantral communication closure and bone regeneration that can meet the needs of an effective, less invasive, and simpler surgery using approaches and biomaterials used in guided bone regeneration (GBR) techniques. The main objective was to close the communication, and the secondary was to achieve bone regeneration.
METHODS: This retrospective and monocentric case series was conducted using data obtained from the medical records of 28 patients with oroantral communications with bone deficits greater than 3 mm and treated with heterologous cortico-cancellous graft covered with resorbable collagen membranes and heterologous cortical lamina. The primary outcome was closure of the communication, and the secondary outcome was bone augmentation, both tested radiographically and clinically.
RESULTS: 28 subjects were treated consecutively for the closure of oroantral communications. The subjects included 16 men and 12 women. The mean age was 57.5 years. Closure was successful in all 28 cases, and radiographic control after 6 months showed bone regeneration in all the cases. This technique was effective in isolating the maxillary sinus from the oral cavity, showing results in terms of seal and healing, and bone regeneration.
CLINICAL SIGNIFICANCE: Oroantral communications are frequent in dentistry, requiring special expertise and interventions affecting patient morbidity. The use of a heterologous cortical lamina can allow effective closure of the communication, preventing migration of pathological epithelia while increasing the bone ridge.
PROBLEM TO BE SOLVED: To obtain a platinum catalyst compsn. excellent in long-term storage stability by mixing a platinum complex having vinyl group-containing organosiloxane as a ligand and vinyl group-containing organopolysiloxane both of which are respectively represented by specific formulae to subject them to heat treatment. SOLUTION: In an addition reaction catalyst of a compsn. consisting of vinyl group-containing organosiloxane and silicon atom bonded hydrogen atom- containing organohydrogenpolysiloxane, a platinum complex having vinyl group- containing organosiloxane as ligand (A) represented by formula I or II is used. Then, organopolysiloxane containing 10mol% or more of a vinyl group in its side chain (B) represented by formula III is mixed with the platinum complex so that the vinyl group in the component (B) becomes 2mol or more per 1mol of a platinum atom in the component (A) and the resulting mixture is heated. In the formulae, R is a monovalent hydrocarbon group with the number of oxygen atoms of 1-8 and (x) and (y) are 10-50 as the number of silicon atoms in one molecule.
In a controlled clinical study with INLYTA for the treatment of patients with RCC, hypertension was reported in 145/359 patients (40%) receiving INLYTA and 103/355 patients (29%) receiving sorafenib. Grade 3/4 hypertension was observed in 56/359 patients (16%) receiving INLYTA and 39/355 patients (11%) receiving sorafenib. Hypertensive crisis was reported in 2/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib. The median onset time for hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) was within the first month of the start of INLYTA treatment and blood pressure increases have been observed as early as 4 days after starting INLYTA. Hypertension was managed with standard anti-hypertensive therapy. Discontinuation of INLYTA treatment due to hypertension occurred in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib [see Adverse Reactions (6.1)].

Ensure that blood pressure is well-controlled prior to initiating INLYTA. Monitor patients for hypertension and treat as needed with standard anti-hypertensive therapy. Withhold and then dose reduce INLYTA or permanently discontinue based on severity of hypertension [see Dosage and Administration (2.2)].
BACKGROUND This study aimed to investigate the association between albumin-corrected anion gap (ACAG) and in-hospital mortality in sepsis-associated acute kidney injury (S-AKI). MATERIAL AND METHODS We conducted this retrospective study based on data from the Medical Information Mart for Intensive Care IV database, and assessed the prognostic capabilities of ACAG in comparison with albumin (ALB) and anion gap (AG) to predict in-hospital mortality of patients with S-AKI. Binomial logistic regression analysis was performed to identify whether ACAG was an independent risk factor for in-hospital mortality for the patients, and receiver operating characteristic (ROC) curves were plotted to clarify its efficacy in predicting in-hospital mortality. We also performed a decision curve analysis (DCA) to determine whether there were net clinical benefits for patients when ACAG was used to predict in-hospital mortality. RESULTS Binary logistic regression analysis showed that ACAG was an independent risk factor for in-hospital mortality in patients with S-AKI, with an area under the ROC (AUC) curve of 0.675 (moderate predictive value) for the prediction of in-hospital mortality, higher than that of ALB or AG alone, with the highest Youden's index (0.2675). The DCA substantiated the superiority of ACAG in net clinical benefits at various threshold probability, enhancing its clinical applicability. CONCLUSIONS The research emphasizes the potential of ACAG as a valuable predictive tool for in-hospital mortality in S-AKI patients, which is better than albumin and AG, encouraging its consideration in clinical practice.
The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled "Baby Bach" and "Baby Mozart" (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy.
Prepn. of dry, oral, prolonged-release compsns. by incorporation of fenspiride, pyribedil or their salts with on or more water-insol. inert diluents having a low compressibility index, and a cellulose ether binding agent which is insoluble in water and non-polar organic solvents, in presence of a solvent or solvent mixt. in which the binding agent is soluble, then converting the mixt. into the final dosage form. Progressive liberation of active constituents, over periods of more than five hrs. Fenspiride gives long-acting control of cough and pyribedil controls disorders of peripheral circulation. A typical coated tablet contained 80 mg. of fenspiride hydrochloride mixed with talc and ethyl cellulose which was granulated with ethanol and dried. The granules were mixed with Mg stearate, compressed and the tablet cores were coated and wax polished.
These participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions. From the week 2-5 of the intervention, the participants will perform the exercises with an adjustable weight vest starting with 2.5% to finally reaching 10% of their body weight.
The Parkinsons disease is a neurodegenerative disease in which dopamine neurons are gradually removed from the substantia nigra of the brain. The inventors have clarified that an ATOX1 fusion protein can protect dopamine neurons from oxidation stress in SH-SY5Y neuroblastoma cells and Parkinsons disease animal models. The ATOX1 fusion protein has been confirmed to be able to smoothly move into SH-SY5Y cell and into the substantia nigra of the brain through a Western blot analysis. The ATOX1 fusion protein remarkably inhibits DNA fragment and production of active oxygen species induced by MPP^+, and the survival of SH-SY5Y cells is eventually induced. In addition, immunohistochemical analyzing data using TH antibody and cresyl violet coloration shows that the ATOX1 fusion protein remarkably protects dopamine cells in the substantia nigra with respect to oxidation stress such as MPTP. Accordingly, the ATOX1 fusion protein can be used in preventing and treating the Parkinsons disease.